MedTrace Logo

Bazedoxifene/Conjugated Estrogens (BZA/CE) Improvement of Metabolism (BIM)

NCT02237079 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2023-06-26

Study results available
· View outcomes & findings →

Summary

The goal of this pilot clinical study is to perform a randomized placebo-controlled study to assess the beneficial effect of a 3 month-treatment with Bazedoxifene/Conjugated Estrogens (BZA/CE) vs. placebo on glucose homeostasis and body composition in 20 post-menopausal women. The recruitment will be performed at Tulane Health Sciences Center.

Conditions

  • Obesity
  • Glucose Homeostasis
  • Postmenopausal Symptoms

Interventions

DRUG

Bazedoxifene/Conjugated Estrogens (BZA/CE)

Daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg.

DRUG

Placebo Oral Tablet

Daily placebo tablet

Sponsors & Collaborators

  • Tulane University Health Sciences Center

    lead OTHER

Principal Investigators

  • Franck Mauvais-Jarvis, MD · Tulane University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2018-04-30
Completion
2018-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02237079 on ClinicalTrials.gov